Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry

Konstantinos I. Votanopoulos,Paul Sugarbaker,M. Deraco,David L. Morris,Olivier Glehen,Dominique Elias,Michele De Simone,M. Robella,B. Heyd,Shigeki Kusamura,D. Baratti,Konstantinos Chouliaras,Greg Russell,Perry Shen,Edward A. Levine

Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry

2018

Konstantinos I. Votanopoulos
Paul Sugarbaker
M. Deraco
David L. Morris
Olivier Glehen
Dominique Elias
Michele De Simone
M. Robella
B. Heyd
Shigeki Kusamura
D. Baratti
Konstantinos Chouliaras
Greg Russell
Perry Shen
Edward A. Levine

Background Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has dramatically improved the survival of patients with epithelioid peritoneal mesothelioma. It is unknown if CRS/HIPEC is indicated for the more aggressive biphasic mesothelioma variant.

Keywords:

Peritoneal mesothelioma
Hyperthermic intraperitoneal chemotherapy
Internal medicine
Biphasic Mesothelioma
Oncology
Medicine
Surgery
peritoneal surface
cytoreductive surgery
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations